sterbo

Alzheimer's Cases May Quadruple by 2050 -

More than 26 million people worldwide have Alzheimer's disease, and a new forecast says the number will quadruple by 2050. At that rate, one in 85 people will have the brain-destroying disease in 40 years, researchers from Johns Hopkins University conclude.

The new estimates, being presented Sunday at an Alzheimer's Association conference in Washington, are not very different from previous projections of the looming global dementia epidemic with the graying of the world's population.

But they serve as a sobering reminder of the toll to come if scientists cannot find better ways to battle Alzheimer's and protect aging brains.

"If we can make even modest advances in preventing Alzheimer's disease, or delay its progression, we could have a huge global public health impact," said Johns Hopkins public health specialist Ron Brookmeyer, who led the new study.

The biggest jump is projected for densely populated Asia, home of almost half of today's Alzheimer's cases, 12.6 million. By 2050, Asia will have 62.8 million of the world's 106 million Alzheimer's patients, the study projects.

A recent U.S. study estimated that this nation's Alzheimer's toll will reach 16 million by 2050, compared with more than 5 million today. The new estimate is significantly lower, suggesting only 3.1 million North American cases today and 8.8 million by 2050.

Among the estimates for other regions are:

_Africa, 1.3 million today and 6.3 million in 2050.
_Europe, 7.2 million and 16.5 million.
_Latin America and the Caribbean, 2 million and 10.8 million.
_Oceania, 200,00 and 800,000.*


Marihuana the best drug for Alzheimer -

The Scripps Research Institute in California found that THC is better at suppressing Alzheimer than any currently approved prescription drug. It 'may provide an improved therapeutic for Alzheimer's disease' that would treat 'both the symptoms and progression' of the disease.

THC is also more effective at blocking clumps of protein that can inhibit memory and cognition in Alzheimer's patients, the researchers reported in the journal Molecular Pharmaceutics. When tested at double the concentration of THC, the commonly described chemical drugs Aricept and Cognex blocked plaque formation only 22 percent and 7 percent as well as THC.

According to the Alzheimer's Association fact sheet -
'Finding a treatment that could delay the onset of Alzheimer's disease by five years could reduce the number of individuals with the disease by nearly 50 percent after 50 years.' **



*Project funded by Elan Pharmaceuticals and Wyeth Pharmaceuticals
**Sources: NORML
.

__________________